Sarepta Therapeutics Inc (SRPT)

35.48
NASDAQ : Health Care
Prev Close 35.48
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.65 / 63.73
Avg Volume 1.90M
Exchange NASDAQ
Shares Outstanding 54.96M
Market Cap 1.94B
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of Its Investigation Of Sarepta Therapeutics, Inc.

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating Sarepta Therapeutics, Inc.

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Big Fund Managers Offer Up Stock Pick Ideas

Big Fund Managers Offer Up Stock Pick Ideas

Hedge fund managers offer up some investment ideas.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Sarepta Therapeutics May Attract Activist Attention

Sarepta Therapeutics May Attract Activist Attention

Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen

Under the Surface, There Are Warnings in This Market

Under the Surface, There Are Warnings in This Market

Small caps are down 0.12% despite the strength in the Nasdaq ETF.

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares

Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal

The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included

5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included

These heavily shorted stocks could get squeezed sharply higher if they report positive earnings this week.

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday.

It's Tough to Figure Out Where to Jump In

It's Tough to Figure Out Where to Jump In

If you aren't positioned long already, you are struggling with what to do here.

My Game Plan Is to Not Trust That Upside

My Game Plan Is to Not Trust That Upside

There has been enough technical damage done lately.

Shark Bites: You Don't Want to Play the Gambler Today

Shark Bites: You Don't Want to Play the Gambler Today

This is one of those days when it may pay to walk away.

Biotech Movers: Sarepta, Bellicum, Novavax

Biotech Movers: Sarepta, Bellicum, Novavax

Sarepta Therapeutics, Bellicum Pharmaceuticals and Novavax were among the biotech stock movers in premarket trading on Wednesday.